Organovo Holdings, Inc. To Present at Cantor Fitzgerald Inaugural Healthcare Conference

Corporate Headquarters

11555 Sorrento Valley Road, Suite 100, San Diego, CA 92121
Tel: (858) 224-1000

Find Us On

Organovo Holdings, Inc. To Present at Cantor Fitzgerald Inaugural Healthcare Conference

SAN DIEGO, June 23, 2015 /PRNewswire/ — Organovo Holdings, Inc. (NYSE MKT: ONVO; “Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using 3D bioprinting technology, announced today that the company will present at the upcoming investor event, the Cantor Fitzgerald Inaugural Healthcare Conference, to be held in New York, July 8, 2015. Keith Murphy, Chairman and Chief Executive Officer, will deliver a company presentation. Mr. Murphy and Barry Michaels, Chief Financial Officer forOrganovo, will be available for individual meetings with investors throughout the day.
Details of the presentations are as follows:


Keith Murphy, Chairman and Chief Executive Officer


Wednesday, July 8, 2015, 10:15 – 10:45 a.m. ET

Organovo’s 3D bioprinting enables the reproducible, automated creation of living human tissues that mimic the form and function of native tissues in the body. The company recently announced collaborations with L’Oreal to produce skin tissue for research and toxicity testing; with Merck to print liver and kidney tissues for studies of drug toxicity and with Yale School of Medicine to develop 3D organ tissues for surgical transplantation research. Organovo was named one of The World’s Top 10 Most Innovative Companies of 2015 in Health Care by Fast Company.
An overview of Organovo’s 3D bioprinting technology is available via video presentation at the Company’s website:
Cantor Fitzgerald’s Inaugural Healthcare Conference is a one-day, multi-track conference featuring presentations from 50+ top tier healthcare companies across the broad continuum of healthcare.  From “bench to bedside”, the conference aims to connect leading public and private healthcare companies with institutional investors, addressing investment opportunities and trends shaping healthcare from the earliest stage of development (“bench”) to patient treatment (“bedside”). With over 50 publicly traded companies and numerous private companies available throughout the day, investors will have the opportunity to expand knowledge and sharpen investment focus, and participate in 1×1 meetings with company management.
For more information about Organovo’s participation in industry events, please visit:
About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human tissues for use in medical research and therapeutic applications. The Company develops 3D human disease models through internal development and in collaboration with pharmaceutical and academic partners. Organovo’s 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. The company recently launched its initial product of the planned exVive3D™ portfolio offering, a 3D Human Liver Tissue for use in Toxicology and other preclinical drug testing. Additional products are in development, with anticipated release for an exVive3D™ Human Kidney Tissue in the latter half of calendar year 2016. The Company also actively conducts early research on specific tissues for therapeutic use in direct surgical applications. In addition to numerous scientific publications, the Company’s technology has been featured in The Wall Street Journal, Time Magazine, The Economist, and numerous other media outlets. Organovo is changing the shape of medical research and practice. Learn more at
Sign up for email updates and connect with us on Twitter (@Organovo).

To view the original version on PR Newswire, visit:

SOURCE Organovo Holdings, Inc.

Organovo Holdings, Inc., Barry Michaels, Chief Financial Officer, 1-858-224-1000 ex. 3,, Gerry Amato, Amato & Partners, LLC,